Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Accured Expenses (2016 - 2025)

Sangamo Therapeutics has reported Change in Accured Expenses over the past 16 years, most recently at -$1.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$1.2 million for Q4 2025, down 109.9% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (down 46.84% YoY), and the annual figure for FY2025 was $3.1 million, down 46.84%.
  • Change in Accured Expenses for Q4 2025 was -$1.2 million at Sangamo Therapeutics, down from $4.0 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for SGMO hit a ceiling of $14.1 million in Q2 2022 and a floor of -$8.3 million in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was $430500.0 (2021), compared with a mean of $784950.0.
  • Biggest five-year swings in Change in Accured Expenses: soared 2342.01% in 2022 and later crashed 1473.68% in 2025.
  • Sangamo Therapeutics' Change in Accured Expenses stood at $2.3 million in 2021, then dropped by 6.03% to $2.2 million in 2022, then surged by 351.11% to $9.8 million in 2023, then increased by 28.89% to $12.6 million in 2024, then tumbled by 109.9% to -$1.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$1.2 million (Q4 2025), $4.0 million (Q3 2025), and -$3.9 million (Q2 2025) per Business Quant data.